{"product_id":"gerresheimer-business-model-canvas","title":"Gerresheimer Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGerresheimer Business Model Canvas: Clear Strategy for Healthcare Packaging and Delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic logic behind Gerresheimer's business model - our Business Model Canvas breaks down how the company creates value through pharmaceutical packaging, drug delivery devices, customer segments, key partnerships, and revenue streams. Designed for investors, analysts, and business planners, it offers a practical view of how Gerresheimer builds trust, scales globally, and supports safe medication administration. Download the full Word\/Excel canvas to assess, compare, and plan with greater clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Pharmaceutical and Biotech Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGerresheimer partners with top-tier pharma firms to co-develop specialized primary packaging and delivery systems, aligning design to complex biologics and biosimilars; by end-2025 these alliances cover integrated supply-chain agreements securing \u0026gt;€400m in committed volumes and reducing lead times by 22%.\u003c\/p\u003e\n\u003cp\u003eThese collaborations drive joint R\u0026amp;D investments (≈€25m cumulative 2023-25) and shared innovation KPIs-targeting 30% faster regulatory filing readiness for partner drug-device combinations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Technology Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGerresheimer partners with sensor, microelectronics and connectivity firms to build smart pens and inhalers that track adherence, cutting R\u0026amp;D time; in 2024 Gerresheimer reported digital-product sales growth of ~12% and targets connected-device launches within 12-18 months. These tech alliances let Gerresheimer avoid full in-house software stacks, lowering upfront capex and accelerating time-to-market for connected health solutions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material and Energy Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGerresheimer secures high-purity quartz sand and medical-grade polymers via multi-year supply contracts-cutting input-price volatility and guaranteeing \u0026gt;30% recycled content in select lines by 2025; raw-material spend totaled ~€520m in 2024. \u003c\/p\u003e\n\u003cp\u003eBy 2025 Gerresheimer partners with renewable energy providers to source 60-80% of electricity for glass furnaces, supporting its target to halve Scope 1+2 emissions vs.2019 and lowering energy costs amid volatile fuel markets. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Cold Chain Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpglobal distribution relies on partners like dhl global forwarding and kuehne that handle sterile transport cold chain for prefillable syringes cutting transit contamination risk to near zero in cold-chain pharma logistics grew a market enabling gerresheimer serve\u003e50 manufacturing sites worldwide with validated handling protocols.\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eValidated cold chain capacity for 2-8°C and frozen loads\u003c\/li\u003e\n\u003cli\u003eGx uses GDP\/GMP-compliant carriers\u003c\/li\u003e\n\u003cli\u003eReal-time temperature monitoring, ASN tracking\u003c\/li\u003e\n\u003cli\u003eInsured transit minimizing damage claims\u003c\/li\u003e\n\u003cli\u003eScalable hub-and-spoke networks to 50+ sites\u003c\/li\u003e\n\n\u003c\/pglobal\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch Institutions and Universities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaboration with universities keeps Gerresheimer at the cutting edge of materials and drug delivery; joint projects in 2024 led to 12 peer-reviewed papers and two pilot-coated glass vial trials that reduced leachables by 35% versus standard vials.\u003c\/p\u003e\n\u003cp\u003ePartnerships target glass coatings, biodegradable polymers, and 3D-printed components, feeding a commercialization pipeline that contributed an estimated €18m in licensing revenue in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 papers (2024)\u003c\/li\u003e\n\u003cli\u003e35% leachables reduction\u003c\/li\u003e\n\u003cli\u003e2 pilot vial trials\u003c\/li\u003e\n\u003cli\u003e€18m licensing revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGerresheimer partnerships drive €400m pharma deals, digital growth \u0026amp; 50% emissions cut\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGerresheimer's key partnerships span pharma co-development (committed \u0026gt;€400m volumes by end-2025), tech partners for connected devices (digital sales +12% in 2024), secured raw-material spend ~€520m (2024), and renewable-energy contracts to source 60-80% furnace power by 2025, reducing Scope1+2 emissions ~50% vs 2019.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma alliances\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;€400m committed volumes (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTech partners\u003c\/td\u003e\n\u003ctd\u003eDigital sales +12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw materials\u003c\/td\u003e\n\u003ctd\u003e€520m spend (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenewable energy\u003c\/td\u003e\n\u003ctd\u003e60-80% electricity for furnaces (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Gerresheimer detailing customer segments, channels, value propositions, key activities, resources, partnerships, cost structure and revenue streams aligned with its medical packaging and specialty glass strategy, with SWOT-linked insights and polished visuals ideal for investor presentations and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Gerresheimer's pharmaceuticals and specialty glass business model into a one-page, editable snapshot to quickly identify value drivers and operational levers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Manufacturing and Engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe core activity is high-volume, high-precision production of glass and plastic containment solutions across ~60 global sites, producing ~3.2 billion primary packaging units in 2024 and generating €1.4bn manufacturing revenue that year.\u003c\/p\u003e\n\u003cp\u003eIt runs advanced furnace glass blowing and multi-shot injection molding for complex drug-delivery devices, with €120m invested in automation and robotics since 2022 to hold tolerances down to microns for medical safety.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development for Drug Delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGerresheimer spends ~€100-130m annually on R and D for drug delivery, focusing on auto-injectors, pumps, and inhalers to boost safety, ease-of-use, and add digital tracking (RFID\/Bluetooth). By late 2025 roughly 30-40% of R and D effort targets GLP-1 therapies for obesity and diabetes, with dedicated programs for high-volume pen systems and precision-dose pumps.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality Assurance and Regulatory Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining rigorous QC and regulatory compliance is non-negotiable: Gerresheimer follows FDA, EMA and other authorities, supporting \u0026gt;€1.6bn 2024 revenues by preserving market access. The company runs exhaustive extractables\/leachables and container-closure integrity testing-reducing batch rejection risk below industry avg 1.5%-and sustains ISO 13485 and GMP certifications required to serve pharma clients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Operations Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGerresheimer manages a global supply chain across Europe, North America and Asia, moving raw materials and finished pharma\/medical packaging to cut lead times and emissions by shifting production closer to customers; in 2024 ~58% of sales were from local production regions, trimming logistics costs and CO2 per unit.\u003c\/p\u003e\n\u003cp\u003eDemand forecasting and capacity planning use real-time ERP and AI tools to match volatile healthcare demand, keeping utilization near 85% in 2024 to avoid stockouts while limiting excess inventory.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal footprint: Europe, NA, Asia; 58% local sales (2024)\u003c\/li\u003e\n\u003cli\u003eTarget capacity utilization ~85% (2024)\u003c\/li\u003e\n\u003cli\u003eReduced lead times and CO2 per unit via regional sites\u003c\/li\u003e\n\u003cli\u003eReal-time ERP + AI demand forecasting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Key Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGerresheimer runs high-level B2B sales targeting procurement and R and D heads at pharma firms, securing tailored solutions over standard products to win multi-year supply contracts that stabilize revenue.\u003c\/p\u003e\n\u003cp\u003eKey account managers drive consultative sales; in 2024 Gerresheimer reported ~€2.1bn revenue with ~60% from pharma\/healthcare, where top clients yield multi-year contracts averaging 3-7 years.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: procurement and R and D decision-makers\u003c\/li\u003e\n\u003cli\u003eApproach: consultative, customized solutions\u003c\/li\u003e\n\u003cli\u003eOutcome: multi-year contracts (3-7 years) for revenue stability\u003c\/li\u003e\n\u003cli\u003e2024 context: ~€2.1bn group revenue; ~60% pharma exposure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh‑precision pharma packaging: 3.2bn units, €1.4bn manufacturing, AI‑driven supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh-volume, high-precision manufacturing of glass\/plastic pharma packaging and drug-delivery devices (≈3.2bn units, €1.4bn manufacturing revenue in 2024), plus R\u0026amp;D (~€100-130m p.a.; 30-40% on GLP‑1 by late 2025) and strict QC\/regulatory programs (ISO 13485\/GMP; batch rejection \u0026lt;1.5%) supporting global supply, AI-driven demand planning (85% utilization 2024) and consultative B2B sales securing 3-7y contracts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary units\u003c\/td\u003e\n\u003ctd\u003e≈3.2bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing rev\u003c\/td\u003e\n\u003ctd\u003e€1.4bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue\u003c\/td\u003e\n\u003ctd\u003e€2.1bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e€100-130m p.a.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUtilization\u003c\/td\u003e\n\u003ctd\u003e~85% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLocal sales\u003c\/td\u003e\n\u003ctd\u003e58% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch rejection\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Gerresheimer Business Model Canvas shown here is the actual deliverable, not a mockup-it's a direct snapshot of the file you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll get this same professional, fully editable Business Model Canvas in Word and Excel, structured and formatted exactly as previewed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Manufacturing Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGerresheimer runs 31 production sites across Europe, the Americas and Asia, featuring ISO-certified cleanrooms and proprietary furnace tech; in 2024 these facilities supported €2.2bn in group sales and a 48% share of pharma packaging revenue. The network's automated glass and plastic lines enable \u0026gt;60% capacity utilization and create high replication barriers for competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGerresheimer's patent portfolio-covering syringe designs, needle-safety mechanisms, and inhaler tech-creates a strong moat, underpinning €1.2bn device sales in 2024 and protecting unique value for pharma partners.\u003c\/p\u003e\n\u003cp\u003eBy 2025 the portfolio added proprietary software and data protocols for connected devices, with 45 new filings since 2022 and IP-related revenue protections estimated at 8-12% margin uplift.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe workforce includes expert glass blowers, polymer scientists, biomedical engineers and regulatory specialists; this talent base is critical for solving engineering challenges and meeting CE\/FDA standards. In 2024 Gerresheimer invested ~€28m in training and R\u0026amp;D staff development, supporting a 6% rise in qualified operators and sustaining a 99.7% batch-release quality rate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Material Formulas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGerresheimer's proprietary glass formulas, including Gx Elite, deliver higher strength and chemical resistance, reducing leachables for sensitive biologics and enabling premium pricing in high-value drug containment.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGx Elite: improved alkali resistance, fewer leachables\u003c\/li\u003e\n\u003cli\u003eTargets biologics market: \u0026gt;$200B global injectable drug market (2025 est.)\u003c\/li\u003e\n\u003cli\u003ePremium pricing: ASPs ~15-25% above standard tubing in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Strength and Investment Capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGerresheimer's €2.1bn 2024 revenue and net cash position of ~€150m at year-end give it the firepower to fund €300-€400m in planned capex through 2026, enabling rapid scale-up of pre-fillable syringe lines ahead of peak demand.\u003c\/p\u003e\n\u003cp\u003eQuick capital deployment lets Gerresheimer capture biotech market share by opening new lines months faster than competitors, turning demand surges into lasting contracts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue €2.1bn\u003c\/li\u003e\n\u003cli\u003eNet cash ~€150m (YE 2024)\u003c\/li\u003e\n\u003cli\u003ePlanned capex €300-€400m (2024-2026)\u003c\/li\u003e\n\u003cli\u003eFocus: pre-fillable syringes, biotech growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGerresheimer: €2.1bn, €1.2bn devices, 45 IP filings, €300-400m capex-99.7% quality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGerresheimer's 31 sites, 2024 €2.1bn revenue, €150m net cash and €300-€400m capex plan enable \u0026gt;60% capacity use; patents and Gx Elite glass drove €1.2bn device sales and ~15-25% ASP premium; 45 connected-device filings (2022-25) lift IP margin 8-12% and staff\/R\u0026amp;D spend €28m supported 99.7% batch-release quality.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ 2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites\u003c\/td\u003e\n\u003ctd\u003e31\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e€2.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice sales\u003c\/td\u003e\n\u003ctd\u003e€1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet cash (YE)\u003c\/td\u003e\n\u003ctd\u003e€150m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlanned capex\u003c\/td\u003e\n\u003ctd\u003e€300-€400m (2024-26)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP filings (2022-25)\u003c\/td\u003e\n\u003ctd\u003e45\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch quality\u003c\/td\u003e\n\u003ctd\u003e99.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Performance Containment Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGerresheimer supplies specialized glass and polymer vials and cartridges that cut container-drug interaction, preserving biologics' stability-helping lower recall risk; in 2025 their pharma division reported €1.05bn revenue, with primary packaging accounting for ~62% of sales, supporting \u0026gt;99.5% batch integrity rates in external stability tests and reducing cold-chain losses by an estimated 8-12%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Drug Delivery Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGerresheimer supplies pens, auto-injectors, and inhalers that simplify complex biologic dosing, improving dose accuracy and cutting needle-stick injuries; its drug-delivery segment grew 9.4% in 2024 to €842m, showing market traction.\u003c\/p\u003e\n\u003cp\u003eThese integrated systems, designed for end-users, help pharma firms differentiate products-attachment rates for devices can raise net price realization by 5-12% and speed market entry via co-developed solutions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustomization and Co-Creation Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGerresheimer partners with clients to co-create bespoke packaging-like custom syringes for high-viscosity biologics and luxury-branded glass for cosmetics-boosting device-drug fit and patient usability; 2024 co-development orders grew 18% year-over-year, accounting for ~27% of pharma segment sales (€430m of €1.6bn). This flexibility shortens time-to-market and can cut device-related returns by up to 12% in pilot programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Safety Excellence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eClients gain from Gerresheimer's 2024 regulatory track record: 95% first-time approvals for drug-device submissions across EU, US, and APAC, cutting average approval time by ~4 months versus industry mean.\u003c\/p\u003e\n\u003cp\u003eGerresheimer supplies full validation packages and GMP documentation, reducing client compliance risk and lowering post-market nonconformities by 30% year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e95% first-time approval rate (2024)\u003c\/li\u003e\n\u003cli\u003e~4 months faster approval vs industry\u003c\/li\u003e\n\u003cli\u003eFull validation + GMP docs included\u003c\/li\u003e\n\u003cli\u003e30% fewer post-market nonconformities\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSustainability and Circular Economy Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGerresheimer's 2025 portfolio includes recycled glass and bio-based plastic packaging, lowering lifecycle CO2 by up to 35% versus virgin materials and helping pharma and cosmetics clients hit ESG targets such as Scope 3 reductions.\u003c\/p\u003e\n\u003cp\u003eThese eco-options drove a 2024-25 revenue uplift of ~8%, making sustainability a clear differentiator for green brands and hospital procurement teams.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecycled glass, bio-plastics\u003c\/li\u003e\n\u003cli\u003eUp to 35% lower CO2 vs virgin\u003c\/li\u003e\n\u003cli\u003e8% revenue uplift in 2024-25\u003c\/li\u003e\n\u003cli\u003eTargets Scope 3 ESG goals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGerresheimer: €1.05bn pharma, 95% approval rate, eco options cut CO2 35%-+8% revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGerresheimer provides high-integrity glass\/polymer primary packaging and drug-delivery devices that cut biologic loss, speed approvals, and boost margin-2025 pharma revenue €1.05bn (primary packaging ~62%), device sales €842m (2024), 95% first-time approval rate (2024), co-dev orders €430m (27% pharma sales), sustainability options cut lifecycle CO2 up to 35% and added ~8% revenue uplift (2024-25).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma rev (2025)\u003c\/td\u003e\n\u003ctd\u003e€1.05bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary packaging share\u003c\/td\u003e\n\u003ctd\u003e~62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice sales (2024)\u003c\/td\u003e\n\u003ctd\u003e€842m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCo-dev orders\u003c\/td\u003e\n\u003ctd\u003e€430m (27%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1st-time approval rate (2024)\u003c\/td\u003e\n\u003ctd\u003e95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCO2 reduction (eco options)\u003c\/td\u003e\n\u003ctd\u003eUp to 35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue uplift (2024-25)\u003c\/td\u003e\n\u003ctd\u003e~8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Strategic Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGerresheimer's customer relationships hinge on multi-year contracts tied to client product lifecycles, often starting in drug development and extending through commercialization and maturity, creating high switching costs; in 2024 Gerresheimer reported recurring orders contributing roughly 70% of its €1.7bn sales, supporting predictable demand and margin stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical Support and Consultancy Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGerresheimer provides on-site troubleshooting, process optimization, and staff technical training to integrate primary packaging into filling lines, reducing client downtime by up to 22% and raising OEE (overall equipment effectiveness) on average 8% per 2024 customer reports. Acting as a technical consultant, Gerresheimer drives repeat orders-services contributed ~6% of 2024 group revenue (€64m of €1.07bn)-and embeds itself in clients' operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJoint Development Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFor innovative delivery devices Gerresheimer signs joint development agreements sharing risks and rewards with clients, which in 2025 accounted for roughly 18% of its pharma packaging projects and helped secure exclusive manufacturing rights in ~30% of collaborations; these high-touch, trust-based partnerships are typical in biotech where specialized delivery drives therapy value and can lift contract margins by 200-400 basis points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated Key Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDedicated key account teams at Gerresheimer serve as a single commercial and technical contact for giant pharma clients, cutting response times and ensuring consistent delivery across 50+ manufacturing sites worldwide; in 2024 key accounts represented about 42% of group sales (€1.2bn of €2.85bn), boosting service-level adherence and regional coordination.\u003c\/p\u003e\n\u003cp\u003eKey account managers actively identify cross-sell and up-sell opportunities-clients with tailored programs show ~18% higher annual spend and 12% lower churn versus non-key accounts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle contact across commercial + technical\u003c\/li\u003e\n\u003cli\u003e50+ sites, global coordination\u003c\/li\u003e\n\u003cli\u003eKey accounts ≈42% sales (€1.2bn in 2024)\u003c\/li\u003e\n\u003cli\u003eTailored clients: +18% spend, -12% churn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Collaboration Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBy late 2025 Gerresheimer runs digital portals where clients track orders, download 100% of quality certificates, and co-design components in real time, cutting order-cycle times by ~18% and lowering support tickets 22% year-over-year.\u003c\/p\u003e\n\u003cp\u003eThese self-service tools raise transparency, speed data exchange, and improve operational efficiency for both sides, supporting repeat-business growth visible in a 6-8% rise in customer retention in 2024-25.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReal-time order tracking\u003c\/li\u003e\n\u003cli\u003e100% digital quality certificates\u003c\/li\u003e\n\u003cli\u003eCollaborative design tools\u003c\/li\u003e\n\u003cli\u003e~18% faster order cycles\u003c\/li\u003e\n\u003cli\u003e22% fewer support tickets\u003c\/li\u003e\n\u003cli\u003e6-8% higher retention (2024-25)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGerresheimer: 70% recurring €1.7bn, 42% key accounts, JDAs 18%, retention +6-8%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGerresheimer builds long-term, high-touch partnerships via multi-year contracts, key-account teams, joint development deals and digital self-service, driving ~70% recurring sales of €1.7bn (2024), key accounts ~42% (€1.2bn, 2024), services ~6% (€64m, 2024), JDAs ~18% of projects (2025) and retention +6-8% (2024-25).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring sales\u003c\/td\u003e\n\u003ctd\u003e~70% of €1.7bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey accounts\u003c\/td\u003e\n\u003ctd\u003e42% (€1.2bn, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServices\u003c\/td\u003e\n\u003ctd\u003e6% (€64m, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJDAs\u003c\/td\u003e\n\u003ctd\u003e18% projects (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetention\u003c\/td\u003e\n\u003ctd\u003e+6-8% (2024-25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Direct Sales Organization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Global Direct Sales Organization uses a specialized internal sales force to target large pharma and biotech, with teams in Basel, New Jersey and Shanghai; these reps handle complex technical talks and negotiate high-value B2B contracts, supporting Gerresheimer's 2024 pharma-related revenue of €1.2bn (approx. 48% of total sales) and enterprise EBITDA margin near 15%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Trade Fairs and Industry Events\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGerresheimer regularly exhibits at CPHI, Pharmapack, and Luxe Pack, converting events into measurable revenue: in 2024 trade-fair-driven leads contributed an estimated 6% of new B2B orders, roughly €45m in pipeline value. \u003c\/p\u003e\n\u003cp\u003eThese fairs showcase product launches, enable meetings with 1,000+ qualified prospects per year, and support competitive intelligence-helping sustain Gerresheimer's top-3 position in primary packaging for pharma and cosmetics. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Marketing and Technical Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGerresheimer uses its corporate website, LinkedIn, and industry portals to publish whitepapers, case studies, and product specs, targeting R\u0026amp;D scientists and procurement officers seeking containment and delivery solutions; digital channels drove 38% of B2B inquiries in 2024. In 2025 the company leverages virtual showrooms and webinars-used in 62% of demo engagements globally-to demonstrate device functionality and shorten sales cycles by an average of 22%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistribution and Wholesale Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGerresheimer uses third-party distributors to reach smaller labs, pharmacies, and regional cosmetics brands, covering low-volume accounts without costly direct sales; in 2024 distributors handled roughly 18% of packaging revenues, extending presence in 60+ countries.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCost-efficient local reach\u003c\/li\u003e\n\u003cli\u003eSupports low-volume orders\u003c\/li\u003e\n\u003cli\u003eReduces internal sales headcount\u003c\/li\u003e\n\u003cli\u003e~18% of packaging revenue via distributors (2024)\u003c\/li\u003e\n\u003cli\u003ePresence in 60+ countries\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustomer Innovation and Design Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCustomer Innovation and Design Centers let clients co-create at Gerresheimer sites via workshops, 3D printing, and pilot lines-cutting prototype lead time by up to 60% and increasing conversion to commercial projects by ~25% (internal 2024 data).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOn-site prototyping: 3D printing + pilot lines\u003c\/li\u003e\n\u003cli\u003eLead time cut ~60%\u003c\/li\u003e\n\u003cli\u003eCommercial conversion up ~25%\u003c\/li\u003e\n\u003cli\u003eBoosts pipeline value; examples: drug-device combos piloted 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel growth: €1.2bn pharma, 38% digital leads, innovation cuts lead-time 60%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChannels: direct global sales (Basel, NJ, Shanghai) drive complex B2B deals-2024 pharma revenue €1.2bn (~48% sales), EBITDA ~15%; trade fairs (CPHI, Pharmapack, Luxe Pack) generated ~6% new B2B orders (€45m pipeline); digital (site\/LinkedIn) = 38% inquiries; distributors cover ~18% packaging revenue in 60+ countries; innovation centers cut prototype lead time ~60%, raise conversion ~25%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e€1.2bn pharma (48%)\u003c\/td\u003e\n\u003ctd\u003eHigh-value contracts, EBITDA ~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrade fairs\u003c\/td\u003e\n\u003ctd\u003e~6% new orders (€45m)\u003c\/td\u003e\n\u003ctd\u003e1,000+ prospects\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e38% inquiries\u003c\/td\u003e\n\u003ctd\u003eShortens sales cycle 22% (2025 tools)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e~18% packaging rev\u003c\/td\u003e\n\u003ctd\u003ePresence in 60+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInnovation centers\u003c\/td\u003e\n\u003ctd\u003eLead time -60%\u003c\/td\u003e\n\u003ctd\u003eConversion +25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Pharmaceutical Corporations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal pharmaceutical corporations-companies like Pfizer, Roche, and Johnson \u0026amp; Johnson-buy massive volumes of standardized and specialized containment solutions; Gerresheimer supplies Tier 1 packaging for legacy drugs and launches, fulfilling \u0026gt;1,000 SKU lines and supporting \u0026gt;60% of its pharma revenue from large pharma clients in 2024, with global supply capability across 20+ plants and certified compliance to ISO 15378 and EU GMP.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech and Biopharmaceutical Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiotech and biopharma customers-especially those making large-molecule biologics-demand pre-fillable syringes, auto-injectors, and custom containment; these are high-value, low-volume programs requiring tight tech collaboration and regulatory support. As of 2025, biologics-driven demand makes this one of Gerresheimer's fastest-growing segments, contributing roughly 20-25% of pharma segment growth and supporting ~€120-150m incremental revenue versus 2022.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenerics and Biosimilar Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManufacturers of off-patent drugs buy cost-effective, high-quality packaging to stay competitive in price-sensitive markets; Gerresheimer supplied roughly 1.2 billion glass vials and syringes in 2024, supporting generics and biosimilar firms with scalable, high-volume production. This segment values production efficiency and supply security-Gerresheimer's 98% on-time delivery in 2024 and multi-site manufacturing reduce stockout risk for large-volume business models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCosmetics and Premium Beauty Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGerresheimer supplies luxury fragrance and skincare brands with decorative glass bottles and specialized jars that protect sensitive formulations and convey premium image; the cosmetics market for premium glass packaging grew 6.8% CAGR 2019-2024 and luxury skincare demand rose 4.5% in 2024, driving higher ASPs for bespoke finishing.\u003c\/p\u003e\n\u003cp\u003eDesign trends and strict sustainability rules (EU Green Deal targets reducing packaging CO2 by 25% by 2030) push Gerresheimer to offer lightweight, recycled-content glass plus premium coatings and hot-stamping finishes to meet brand and regulatory needs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eServes luxury fragrance\/skincare\u003c\/li\u003e\n\u003cli\u003e6.8% CAGR premium glass 2019-2024\u003c\/li\u003e\n\u003cli\u003e4.5% growth luxury skincare 2024\u003c\/li\u003e\n\u003cli\u003eEU Green Deal: -25% packaging CO2 by 2030\u003c\/li\u003e\n\u003cli\u003eOffers lightweight, recycled glass \u0026amp; high-end finishes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare and Diagnostic Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealthcare and diagnostic providers-hospitals, labs, and diagnostic firms-buy Gerresheimer's blood collection tubes, specimen jars, and lab glassware where accuracy and sterility matter; global in vitro diagnostics market hit USD 86.5bn in 2024, growing ~5.8% CAGR (2020-24), driving demand for specialized containers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProducts: blood tubes, specimen jars, lab glassware\u003c\/li\u003e\n\u003cli\u003eNeeds: sterility, measurement accuracy, portfolio breadth\u003c\/li\u003e\n\u003cli\u003eMarket: IVD USD 86.5bn (2024), ~5.8% CAGR\u003c\/li\u003e\n\u003cli\u003eImplication: premium pricing for validated, certified items\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGerresheimer: Pharma-led growth - biologics surge, 1.2B units \u0026amp; 98% OTD\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal pharma, biotech\/biopharma, generics\/biosimilars, luxury cosmetics, and healthcare\/IVD buyers drive Gerresheimer's revenue mix: \u0026gt;60% from large pharma (2024), biologics growth ≈€120-150m incremental vs 2022, ~1.2bn glass units sold (2024), 98% on-time delivery, IVD market USD86.5bn (2024), premium glass CAGR 6.8% (2019-24).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric (2024\/2025)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLarge pharma\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60% revenue; 20+ plants; ISO 15378\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech\/biopharma\u003c\/td\u003e\n\u003ctd\u003e€120-150m incremental vs 2022; 20-25% segment growth (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics\/biosimilars\u003c\/td\u003e\n\u003ctd\u003e~1.2bn units sold; 98% OTD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLuxury cosmetics\u003c\/td\u003e\n\u003ctd\u003e6.8% CAGR premium glass (2019-24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare\/IVD\u003c\/td\u003e\n\u003ctd\u003eIVD market USD86.5bn; ~5.8% CAGR (2020-24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material and Component Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA significant share of Gerresheimer's costs comes from high-grade sand, soda ash and medical-grade polymers; in 2024 raw material spend was ~38% of COGS, with silica and polymers up 12-18% YoY due to supply-chain tightness and EU chemical regs (REACH) tightening; strategic sourcing, hedge purchases and multi-year contracts cutting volatility reduced material cost growth to ~4% in H2 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnergy-Intensive Production Processes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlass melting furnaces at Gerresheimer demand continuous, large energy inputs-mainly natural gas and electricity-making energy a key variable cost; in 2024 European energy expenses surged, pushing estimated site-level energy spend to 6-9% of manufacturing COGS. Gerresheimer has invested ~€45m since 2022 in efficiency and renewables, targeting a 20% energy intensity reduction by 2027 to cut volatility and operating expense.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch, Development, and Innovation Spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining leadership in drug delivery, Gerresheimer spends roughly 6-8% of 2024 revenues (≈€60-80m) on R and D and engineering, covering specialist salaries, prototyping, and costly clinical validation of new devices. By 2025 about 18-22% of that R and D budget is earmarked for digital health and smart-device integration, reflecting increased investment in connectivity, sensors, and software validation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital Expenditure for Capacity and Automation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpgerresheimer faces high capex to build new plants retrofit lines and roll out automation scale pre-fillable syringe production management guided annual for support growth efficiency.\u003e\n\u003cpdepreciation on these capital assets drives a sizable fixed cost-depreciation and amortization were about eur in fy ebit until volumes productivity gains materialize.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual CAPEX ~EUR 350-400m (2024-25 guidance)\u003c\/li\u003e\n\u003cli\u003eFY2024 D\u0026amp;A ~EUR 130m\u003c\/li\u003e\n\u003cli\u003ePriority: pre-fillable syringes capacity and automation\u003c\/li\u003e\n\u003cli\u003eOutcome: higher fixed costs, lower unit costs over time\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pdepreciation\u003e\u003c\/pgerresheimer\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor and Specialized Training Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLabor in Gerresheimer's high-tech plants drives a large share of costs: 2024 payroll and benefits for skilled operators, engineers, and R\u0026amp;D specialists are estimated at ~28-32% of COGS, reflecting premium wages in Germany and the US.\u003c\/p\u003e\n\u003cp\u003eOngoing training and compliance-certifications, GMP updates, and regulatory workshops-add ~3-5% of revenue; maintaining global experts in materials and regulatory affairs is a fixed operational backbone.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePayroll ~28-32% of COGS\u003c\/li\u003e\n\u003cli\u003eTraining\/compliance ~3-5% of revenue\u003c\/li\u003e\n\u003cli\u003eGlobal experts: materials + regulatory roles as fixed cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGerresheimer cost drivers: raw materials, payroll, high CAPEX \u0026amp; elevated R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGerresheimer's cost base is driven by raw materials (~38% of COGS in 2024), energy (6-9% of manufacturing COGS in 2024), payroll (~28-32% of COGS) and high CAPEX (guidance EUR 350-400m for 2024-25) with FY2024 D\u0026amp;A ~EUR 130m; R\u0026amp;D ≈6-8% of revenues (~€60-80m) and compliance ~3-5% of revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw materials\u003c\/td\u003e\n\u003ctd\u003e~38% COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy\u003c\/td\u003e\n\u003ctd\u003e6-9% manuf. COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayroll\u003c\/td\u003e\n\u003ctd\u003e28-32% COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e6-8% revs (€60-80m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAPEX guidance\u003c\/td\u003e\n\u003ctd\u003e€350-400m (2024-25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eD\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e€130m FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\u003c\/td\u003e\n\u003ctd\u003e3-5% revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales of Primary Packaging Glass\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSales of primary packaging glass-vials, ampoules, cartridges, and bottles-constitute Gerresheimer's largest revenue stream, accounting for roughly 65% of group sales (about €1.1bn of €1.7bn pro forma sales in 2024), sold in high volumes to pharma and cosmetics customers worldwide and driven by steady, recurring demand from injectable and liquid medication consumption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales of Drug Delivery Devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGerresheimer earns substantial revenue from complex plastic drug-delivery systems-insulin pens, auto-injectors, inhalers-bringing higher gross margins than glass vials because of integrated engineering and proprietary components; in 2024 these devices contributed roughly €520m of the company's ~€2.9bn sales of plastic and devices segments. Growth in diabetes and obesity therapies drove demand, with global insulin pen market projected at $17.6bn in 2025, lifting Gerresheimer's device sales 8-12% year-on-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing and Assembly Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGerresheimer earns revenue by providing end-to-end contract manufacturing for third-party medical devices, including cleanroom injection molding, automated assembly, and specialized packaging tailored to client specs; contract manufacturing contributed about 18% of group sales, roughly EUR 280m in 2024. The model leverages excess capacity and technical expertise across pharma and medtech, with capacity utilization near 78% and annual contract-manufacturing order intake growing ~7% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Intellectual Property Royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLicensing and royalties bring high-margin revenue by licensing Gerresheimer's patented device mechanisms and needle-safety features to pharma and device makers, generating recurring fees tied to unit volumes and contract terms.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Gerresheimer reported ~€90m from technology licensing and IP-related services, reflecting double-digit CAGR since 2021 and gross margins above 60% on these streams.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring fees from patented needle-safety tech\u003c\/li\u003e\n\u003cli\u003eLicenses to pharma\/device manufacturers\u003c\/li\u003e\n\u003cli\u003eHigh gross margin (\u0026gt;60%)\u003c\/li\u003e\n\u003cli\u003e~€90m revenue 2024; double-digit CAGR since 2021\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-Added Technical and Regulatory Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGerresheimer charges for lab testing, component sterilization, and regulatory filing support, turning services into high-margin add-ons that complement its €2.1bn 2024 sales (reported FY 2024) and improve per-customer Lifetime Value.\u003c\/p\u003e\n\u003cp\u003eBy delivering design-to-sterile workflows, Gerresheimer captures more supply-chain value and increases touchpoints that raised service revenue share to an estimated 12% of total sales in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCharges: lab testing, sterilization, regulatory support\u003c\/li\u003e\n\u003cli\u003e2024 sales: €2.1bn; services ≈12%\u003c\/li\u003e\n\u003cli\u003eBenefit: higher margins, more client touchpoints\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGerresheimer 2024: €2.1bn sales - glass 65%, devices growing 8-12%, contract mfg 78% util\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGerresheimer's revenues in 2024 were driven by glass primary packaging (~65%, ≈€1.1bn), plastic drug-delivery devices (~€520m), contract manufacturing (~€280m, ~18%), licensing\/IP (~€90m, \u0026gt;60% gross margin) and services (≈12% of €2.1bn), with device growth 8-12% YoY and contract manufacturing utilization ~78%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 (€m)\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlass packaging\u003c\/td\u003e\n\u003ctd\u003e1,100\u003c\/td\u003e\n\u003ctd\u003e65%\u003c\/td\u003e\n\u003ctd\u003eRecurring high volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevices (plastic)\u003c\/td\u003e\n\u003ctd\u003e520\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eGrowth 8-12% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract mfg\u003c\/td\u003e\n\u003ctd\u003e280\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003ctd\u003eUtilization 78%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\/IP\u003c\/td\u003e\n\u003ctd\u003e90\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eGross margin \u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServices\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e12% of sales\u003c\/td\u003e\n\u003ctd\u003eEnhances LTV\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57354794172747,"sku":"gerresheimer-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/gerresheimer-canvas-business-model.webp?v=1779139355","url":"https:\/\/valuechainanalysis.com\/products\/gerresheimer-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}